抗结核固定剂量复合剂(FDC)治疗初治活动性肺结核的临床治疗效果刍议  

Discussion on the Clinical Therapeutic Effect of Anti-tuberculosis Fixed-dose Compound (FDC) in the Treatment of Newly-treated Active Pulmonary Tuberculosis

作　　者：赵玉杭[1] 谢文芳 李佳[1] 黄玲[1] 羊晶晶[1] ZHAO Yuhang;XIE Wenfang;LI Jia;HUANG Ling;YANG Jingjing(Department of Tuberculosis Control,Fuzhou Center for Disease Control and Prevention,Fuzhou,Fujian Province,350001 China;Fuzhou Tuberculosis Prevention and Treatment Hospital,Fuzhou,Fujian Province,350001 China)

机构地区：[1]福州市疾病预防控制中心结核病防治科,福建福州350001 [2]福州结核病防治院,福建福州350001

出　　处：《中外医疗》2021年第35期4-7,共4页China & Foreign Medical Treatment

摘　　要：目的研究抗结核固定剂量复合剂(FDC)治疗初治活动性肺结核的临床治疗效果。方法随机选取2017年1月—2021年1月期间就诊福州市各结核病定点医院的300例初治活动性肺结核患者,以随机抽取方式进行对等分组,A组(n=150)采用常规抗结核药物方案治疗;B组(n=150)采用抗结核固定剂量复合剂(FDC)治疗,总结分析两组患者的临床治疗效果。结果治疗后第2、6个月时,B组的病灶吸收率40.00%、54.46%,病灶缩小率52.67%、54.46%与A组的38.00%、48.00%、47.33%以及51.33%比较,差异无统计学意义(χ^(2)=0.126、1.334、0.853、0.334,P>0.05);但B组病灶吸收的总有效率为91.33%相较于A组的74.67%明显更高,差异有统计学意义(χ^(2)=14.764,P<0.05);治疗后,第2、5及6个月时,B组患者的痰菌阴转率55.33%、83.33%及96.00%相较于A组的38.00%、72.67%、80.67%明显更高,差异有统计学意义(χ^(2)=9.053、4.972、17.110,P<0.05);B组药物不良反应发生率为5.33%,与A组4.00%对比,差异无统计学意义(χ^(2)=0.299,P>0.05)。结论抗结核固定剂量复合剂用于初治活动性肺结核效果良好,且安全性高,建议临床对此药物进行积极推广应用。Objective To study the clinical therapeutic effect of anti-tuberculosis fixed-dose combination(FDC)in the treatment of newly treated active pulmonary tuberculosis.Methods Randomly selected 300 cases patients with newly-treated active tuberculosis in designated tuberculosis hospitals in Fuzhou were treated from January 2017 to January 2021 and divided into equal groups by random selection,group A(n=150)treated with conventional anti-tuberculosis drug regimen,group B(n=150)with anti-tuberculosis fixed-dose combination(FDC)treatment,the clinical treatment effects of the two groups of patients were summarized and analyzed.Results At the second and sixth months after treatment,the lesion absorption rate of group B was 40.00%,54.46%,and the lesion reduction rate of 52.67%,54.46%was comparable to 38.00%,48.00%,47.33%,and 51.33%of group A,the difference was not statistically significant(χ^(2)=0.126,1.334,0.853,0.334,P>0.05).However,the total effective rate of lesion absorption in group B was 91.33%compared with 74.67%in group A,the difference was statistically significant(χ^(2)=14.764,P<0.05).After treatment,at 2,5,and 6 months,the negative conversion rate of sputum bacteria in group B was 55.33%,83.33%,and 96.00%,compared with 38.00%,72.67%,and 80.67%in group A,which were significantly higher,the difference was statistically significant(χ^(2)=9.053,4.972,17.110,P<0.05).The incidence of adverse drug reactions in group B was 5.33%compared with 4.00%in group A,the difference was not statistically significant(χ^(2)=0.299,P>0.05).Conclusion The anti-tuberculosis fixed-dose combination(FDC)has a good effect in the initial treatment of active pulmonary tuberculosis and has high safety.It is recommended that this drug be actively promoted and applied in clinics.

关 键 词：抗结核 固定剂量复合剂 初治 活动性肺结核 药物疗法 疗效观察 

分 类 号：R521[医药卫生—内科学]